NovaLead Pharma Pvt. Ltd.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
NovaLead Pharma Pvt. Ltd. - overview
Location
Pune, Maharashtra, India
Primary Industry
Pharmaceuticals
About
NovaLead Pharma Pvt. Ltd. specializes in drug discovery and repurposing, focusing on transforming existing generic drugs into effective treatments for difficult medical conditions. NovaLead Pharma Pvt.
Ltd. is a Pune, India-based company that operates in the pharmaceutical sector, concentrating on drug discovery and repurposing. Founded by Supreet Deshpande, the company has not undergone significant strategic pivots since its inception. In April 2010, Tata Capital Private Equity acquired a minority stake for USD 8 million.
The company has raised a total of INR 18. 770 mn in funding, with its last round occurring in April 2010. Currently, NovaLead Pharma is valued at INR 918. 378 mn.
NovaLead Pharma focuses on drug discovery and repurposing, with a strong emphasis on developing new indications for existing generic drugs. Their flagship product, Galnobax®, is a topical gel aimed at treating hard-to-heal Diabetic Foot Ulcers (DFUs), having successfully completed Phase III clinical trials. Additionally, the company is advancing NLP91, a candidate for treating inflammatory skin diseases like psoriasis, which has received patent approval in the United States. NovaLead's products are primarily marketed within India, with plans to expand into international markets where there is significant unmet medical need.
In 2023, NovaLead Pharma recorded a revenue of INR 637,621. 70, with an EBITDA of INR 320,125. 10. The company generates revenue through licensing agreements and partnerships, particularly leveraging its relationships with firms like Ipca Laboratories to market Galnobax® in India.
Their pricing structure positions products such as Galnobax® as premium treatments, reflecting the pharmaceutical market standards. NovaLead Pharma is actively working on expanding its portfolio and market reach. The company plans to launch additional products and is targeting new geographic regions for growth, focusing on markets that demonstrate significant unmet medical needs. Recent funding from Tata Capital Private Equity will bolster these initiatives, enabling NovaLead to enhance its product development and expand its marketing efforts.
The company's strategic aim is to solidify its presence in both domestic and international markets by addressing critical health challenges, particularly in the diabetic population.
Current Investors
Tata Capital , Kotak Alternate Asset Managers
Primary Industry
Pharmaceuticals
Sub Industries
Pharmaceutical Research & Development
Website
http://www.novaleadpharma.com
Total Amount Raised
Subscriber access only
NovaLead Pharma Pvt. Ltd. - timeline of key events
NovaLead Pharma Pvt. Ltd. - financials
| Fiscal Year Ended | Mar 31, 2012 | Mar 31, 2013 | Mar 31, 2014 | Mar 31, 2015 | Mar 31, 2016 | Mar 31, 2017 | Mar 31, 2018 | Mar 31, 2019 | Mar 31, 2020 | Mar 31, 2021 | Mar 31, 2022 | Mar 31, 2023 | Mar 31, 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | - | - | - | 26,875,544 | 12,402,742 | 13,085,662 | 7,776,677 | 7,721,847 | 9,630,628 | 8,922,059 | - | - | - |
| % Revenue Growth (YoY) | - | - | - | - | (53.9%) | 5.5% | (40.6%) | (0.7%) | 24.7% | (7.4%) | - | - | - |
| EBITDA (USD) | - | (33,673,588) | (28,575,948) | 4,069,153 | (14,982,964) | (12,069,187) | (15,002,344) | (4,708,152) | 6,134,255 | (10,230,964) | - | - | - |
| Operating Income (USD) | - | (33,772,972) | (36,059,274) | (6,502,973) | (24,235,864) | (20,299,149) | (20,581,333) | (10,139,277) | 1,277,928 | (15,388,419) | - | - | - |
| Operating Margin | - | - | - | (24.2%) | (195.4%) | (155.1%) | (264.7%) | (131.3%) | 13.3% | (172.5%) | - | - | - |
| % EBITDA Margin | - | - | - | 15.1% | (120.8%) | (92.2%) | (192.9%) | (61.0%) | 63.7% | (114.7%) | - | - | - |
| NET Income (USD) | (54,644,532) | (33,515,239) | (35,794,658) | (14,527,981) | (24,379,715) | (20,750,763) | (21,048,705) | (10,476,592) | 1,614,494 | (15,372,833) | - | - | - |
| % Net Margin | - | - | - | (54.1%) | (196.6%) | (158.6%) | (270.7%) | (135.7%) | 16.8% | (172.3%) | - | - | - |
NovaLead Pharma Pvt. Ltd. - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Growth | Completed | NovaLead Pharma Pvt. Ltd. | - |
Displaying 1 - 1 of 1
NovaLead Pharma Pvt. Ltd. - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.